Analist is and analysis by drs. E. (Erik) D. Molenaar RBA, RBA/CFA certified investment analist and EFFAS certified financial analist. Delivering to the point investment analysis. Apart from an absolute advice, a clear sector advice and overview, and/or a relative advice within the sector, is always included in the reports which makes the reports extremely usefull and helpfull for fund allocation within a sector.
BUSINESS ACCOUNT
Access reports individually or via Subscription
Receive monthly invoices with payment via CSA or hard dollars
Analyst access
Free Trial Subscriptions
Team account with shared subscriptions
Advanced analytics to track research consumption and performance
Abbvie with sector report. The company has been compared with 16 other pharmaceutial and biotechnoly companies. Helpfull with easy and appropriate fund allocation guidelines within the sector. Abbvie its high amount of debt catches the eye and is somewhat special.
Abbvie en sectorrapport. Het aandeel wordt vergeleken met 16 andere sector genoten. Het rapport bevat tegelijkertijd een sector rapport waardoor de toewijzing van middelen binnen de sector farmacie en biotechnologie aan individuele aandelen zowel ondersteunend als gemakkelijk wordt.
Includes full sector report with 17 healthcare and biotechnology companies, where Johnson & Johnson is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Biogen, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology s...
Includes full sector report with 17 healthcare and biotechnology companies, where Biogen is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Merck, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology s...
Includes full sector report with 17 healthcare and biotechnology companies, where Merck is analysed in relative perspective of Abbott Laboratories, Abbvie, Amgen, AstraZeneca plc, Bayer AG, Biogen, Bristol-Myers Squibb Co, Eli Lilly Co, Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Novartis, Novo Nordisk A/S, Pfizer, Roche Holding ltd. Gnns and Sanofi. Ready to implement with standard portfolio. This report makes it clear how to allocate funds within the healthcare and biotechnology s...
